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and All-Cause Mortality in
Patients With Type 2 Diabetes
(ZODIAC-30)
OBJECTIVE
The midregional fragment of proadrenomedullin (MR-proADM) is a marker of
endothelial dysfunction and has been associated with a variety of diseases. Our
aim was to investigate whether MR-proADM is associated with new-onset
albuminuria and cardiovascular (CV) and all-cause mortality in patients with type
2 diabetes treated in primary care.
RESEARCH DESIGN AND METHODS
Patients with type 2 diabetes participating in the observational Zwolle Outpatient
Diabetes Project Integrating Available Care (ZODIAC) study were included. Cox
regression analyses were used to assess the relation of baselineMR-proADMwith
new-onset albuminuria and CV and all-causemortality. Risk prediction capabilities
of MR-proADM for new-onset albuminuria and CV and all-cause mortality were
assessed with Harrell’s C and the integrated discrimination improvement.
RESULTS
In 1,243 patients (mean age 67 [612] years), the median follow-up was 5.6 years
(interquartile range 3.1–10.1); 388 (31%) patients died, with 168 (12%) CV deaths.
Log2 MR-proADM was associated with CV (hazard ratio 1.96 [95% CI 1.27–3.01])
and all-cause mortality (1.78 [1.34–2.36]) after adjusting for age, sex, BMI,
smoking, systolic blood pressure, cholesterol-to-HDL ratio, duration of diabetes,
HbA1c, ACE inhibitor/angiotensin receptor blocker, history of CV diseases, log
serum creatinine, and log albumin-to-creatinine ratio. MR-proADM slightly im-
proved mortality risk prediction. The age- and sex-adjusted, but not multivariate-
adjusted, MR-proADM levels were associated with new-onset albuminuria.
CONCLUSIONS
MR-proADM was associated with CV and all-cause mortality in patients with type
2 diabetes after a median follow-up of 5.6 years. There was no independent re-
lationship with new-onset albuminuria. In the availability of an extensive set of
risk factors, there was little added effect of MR-proADM in risk prediction of CV
and all-cause mortality.
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Endothelial dysfunction in patients with
type 2 diabetes is associated with
cardiovascular (CV) complications (1).
The peptide hormone adrenomedullin
(ADM) appears to have a role in the
pathophysiology of endothelial
dysfunction (2–4). ADM has a role as a
circulating hormone as well as a
paracrine regulator of cell function (5).
Endothelial cells highly express the
mRNA of ADM and actively synthesize
and secrete ADM (6). Increased plasma
levels of ADM lead to a number of
physiological effects, such as induction
of vasodilation and hypotension,
increased glomerular filtration rate,
fractional sodium excretion, and
increased cardiac output (7,8). ADM
could exert a protective effect against
cardiac hypertrophy and fibrosis in
ADM-knockout mice by attenuating
remodeling (9). ADM infusion increases
renin levels and decreases plasma
aldosterone levels in patients with heart
failure (10), and a search for drugs
targeting ADM is ongoing (11–15).
The nonfunctional midregional
fragment of the prohormone of ADM
(MR-proADM) can be used as a
surrogate marker of ADM and predicts
early CV mortality (16). ADM synthesis
is increased in response to vascular
injury and counterbalances negative
processes, and unlike ADM, MR-proADM
is stable and the longer half-life results
in a 1,000-fold higher concentration
than ADM (4,17). Increased plasma
MR-proADM levels are also associated
with the development of CV morbidity
and have a role in predicting adverse
outcomes in patients with coronary
artery disease (14,16) and heart failure
(15,17) and patients presenting to the
emergency department with dyspnea
(18). MR-proADM may also be useful
for excluding the diagnosis of left
ventricular failure (19), predicting
the response to antimicrobials and
estimating prognosis in patients with
sepsis (20,21). Few studies exist with
long-term follow-up (22). In patients
with type 2 diabetes, increased levels
of MR-proADM have been associated
with an increased risk for CV events
after short-term follow-up (23).
There are no studies investigating the
relationship between plasmaMR-proADM
levels and mortality after long-term
follow-up in patients with type 2
diabetes, nor are there studies
investigating the relationship with
new-onset albuminuria, another
marker of endothelial dysfunction.
This study aimed to investigate the
association with and predictive
capabilities of MR-proADM and new-
onset albuminuria and CV and all-cause
mortality in patients with type 2
diabetes (24–26).
RESEARCH DESIGN AND METHODS
Study Group
The Zwolle Outpatient Diabetes Project
Integrating Available Care (ZODIAC)
study was initiated in 1998 in the Zwolle
region of the Netherlands. The design
and details of this study have been
published previously (27). Patients
with a very short life expectancy
(including patients with active cancer)
or insufficient cognitive abilities were
excluded from participation in this
study. In the first year, 1,143 patients
with type 2 diabetes were included in
this prospective cohort study. In 2001,
546 patients with type 2 diabetes were
additionally enrolled, resulting in a
combined cohort of 1,689 patients,
treated exclusively in primary care
(28). Of the 1,689 included patients,
1,374 samples were eligible for further
analyses to measure plasma MR-
proADM. Plasma MR-proADM values
could be measured in 1,243 available
samples. The ZODIAC study was
approved by the local medical ethics
committee, and all patients provided
informed consent.
Data Collection and Measurements
Baseline data were collected in 1998
and 2001, consisting of a full medical
history, including a history of CV
diseases (CVDs), use of medication, and
tobacco consumption. Patients were
considered to have a history of CVD if
they had a history of angina pectoris,
myocardial infarction, percutaneous
transluminal coronary angioplasty,
coronary artery bypass grafting, stroke,
or transient ischemic attack. Laboratory
and physical assessment data were
collected at baseline and included
nonfasting lipid profile, HbA1c, serum
creatinine (SCr), urinary albumin-to-
creatinine ratio (ACR), and blood
pressure. SCr was measured by a kinetic
colorimetric Jaffe method (Modular
P Analyzer; Roche, Almere, the
Netherlands), ACR was measured using
immunonephelometry (Behring
Nephelometer; Behring, Mannheim,
Germany), and blood pressure was
measured twice with a Welch Allyn
sphygmomanometer in supine position
after at least 5 min of rest. Albuminuria
was defined as an ACR .2.5 mg/mmol
for men and.3.5mg/mmol for women.
MR-proADM was measured in plasma
samples collected at baseline. Plasma
MR-proADM was measured using a
commercial assay in the
chemiluminescence/coated tube
format (MR-proADM LIA; B.R.A.H.M.S
GmbH, Thermo Fisher Scientific,
Hennigsdorf, Germany) (17). The lower
limit of detection of the assay is 0.08
nmol/L. The functional assay sensitivity
(defined as the lowest concentration
detectable with an interassay
coefficient of variability of 20%) is 0.11
nmol/L. The intra-assay coefficients of
variability at 0.5 and 5 nmol/L are 3 and
3.5%, respectively; the interassay
coefficients of variability at 0.5 and
5 nmol/L are 8.5 and 6.5%. Prolonged
frozen storage and repeated freeze-
thaw cycles have no effect on
MR-proADM values (17). MR-proADM is
produced in equimolar masses (4,17).
MR-proADM follows a Gaussian
distribution with a mean (SD) of 0.33
nmol/L (0.07) (17). There is a trend to
higher MR-proADM values in older
individuals. Values are very stable
during the day and not influenced by
food or water intake.
Clinical End Points and Follow-up
The end points of this study were
1) new-onset albuminuria, 2) CV
mortality, and 3) all-cause mortality.
Patients were regarded as new-
onset albuminuria when they 1) had
normoalbuminuria at baseline and
developed albuminuria in two
consecutive follow-up years; 2) had
normoalbuminuria at baseline and
showed albuminuria in at least one
single follow-up year, followed by
initiation of an ACE inhibitor (ACEi) or
angiotensin-II antagonist treatment
in the same year; and 3) were
normoalbuminuric on ACEi/angiotensin-
II antagonist treatment at baseline and
developed albuminuria in at least one of
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the follow-up years. In 2009, vital status
and cause of death were retrieved from
records maintained by the hospital and
the general practitioners for the first
1,143 patients. For the additional 546
patients, vital status and cause of death
were retrieved in 2005. Causes of death
were coded according to the ICD-9. CV
death was defined as death in which the
principal cause of death was CV in
nature, using ICD-9 codes 390–459.
Statistical Analyses
Cox regression analyses were used to
analyze the risk of new-onset albuminuria
and CV and all-cause mortality during
follow-up. MR-proADM and ACR
followed a non-Gaussian distribution, and
log2 transformations were applied so the
hazard ratios (HRs) derived were
expressed as an increase in risk per
doubling of baseline MR-proADM values.
Four models were used: 1) a crude
model, 2) a model adjusted for age, sex,
and MR-proADM, 3) a fully adjusted
model (BMI, smoking, systolic blood
pressure, cholesterol-to-HDL ratio,
duration of diabetes, HbA1c, history of
CVD, use of ACEi/angiotensin receptor
blocker [ARB], log SCr, and log ACR) with
MR-proADM, and 4) a fully adjusted
model without MR-proADM. The
assumption of proportional hazards for
baseline predictors was investigated by
inspecting the Schoenfeld residuals. Cox
regression analyses were used to test
whether an association existed between
the presence or absence of a MR-
proADM measurement and new-
onset albuminuria and CV and all-cause
mortality. The effect on the fit of the
fully adjusted models by including MR-
proADM in the models was tested using
the likelihood ratio test.
The possible additional value of MR-
proADM for the risk prediction of new-
onset albuminuria and CV and all-cause
mortality was assessedwith the receiver
operating characteristic analysis (using
Harrell’s C) and the integrated
discrimination improvement (IDI). The
Harrell’s C and the IDI were used to
investigate the predictive capability of
eachmodel. The IDI can be interpreted as
the difference between model-based
probabilities for events and nonevents for
the models with and without MR-
proADM, although the IDI has been
criticized (29). Calibration, a measure to
evaluate how well predicted probabilities
agree with observed risks, was assessed
using the Grønessby and Borgan
“goodness-of-fit” likelihood-ratio
Table 1—Baseline patient characteristics of the study population (n = 1,243)
presented as tertiles of MR-proADM concentration
Tertile 1 Tertile 2 Tertile 3 P value
MR-proADM (nmol/L) ,0.425 0.425–0.526 .0.526
n 415 413 415
Deceased (n, %) 70 (17) 110 (27) 208 (50)
Follow-up time (years) 9.8 6.0 6.1
Age (years) 60 6 11 68 6 10 67 6 10 0.00
Smoking (%) 22 19 16 0.40
History of CVD (%) 23 30 51 0.00
BMI (kg/m2) 28 6 4 29 6 5 29 6 5 0.00
Systolic blood pressure (mmHg) 148 6 24 155 6 24 154 6 24 0.00
Use of ACEi/ARB (%) 18 24 40 0.00
Cholesterol-to-HDL ratio 4.9 6 1.5 4.7 6 1.4 4.7 6 1.4 0.31
Use of lipid-lowering drugs (%) 14 16 15 0.32
Duration of diabetes (years) 4 (2–9) 4 (2–9) 4 (2–9) 0.16
HbA1c (%) 7.3 6 1.3 7.3 6 1.4 7.3 6 1.4 0.29
ACR (mg/mmol) 1.5 (0.8–3.8) 1.9 (0.9–5.7) 1.9 (0.9–5.8) 0.00
SCr (mmol/L) 89 6 15 89 6 15 89 6 15 0.00
Data are expressed as mean 6 SD or median (IQR), unless otherwise specified.
Table 2—HRs and additional value of baseline log2 MR-proADM concentrations in risk prediction compared with established
CV risk markers
Model 1 Model 2 Model 3 Model 4
New-onset albuminuria
HR (95% CI) 1.83 (1.32–2.54) 1.46 (1.01–2.10) 1.40 (0.94–2.10) NA
Harrell’s C (95% CI) 0.58 (0.53–0.63) 0.65 (0.61–0.69) 0.70 (0.66–0.74) 0.70 (0.66–0.74)
Grønnesby and Borgan test 0.17 0.77 0.64 0.63
IDI % (P value) NA 0.006 (0.01) 0.003 (0.25) NA
CV mortality
HR (95% CI) 5.89 (4.43–7.99) 3.68 (2.59–5.23) 1.96 (1.27–3.01) NA
Harrell’s C (95% CI) 0.72 (0.68–0.77) 0.78 (0.74–0.82) 0.82 (0.78–0.85) 0.81 (0.78–0.85)
Grønnesby and Borgan test 0.04 0.86 0.01 0.08
IDI % (P value) NA 0.03 (P = 0.0001) 0.002 (P = 0.3) NA
All-cause mortality
HR (95% CI) 4.49 (3.65–5.52) 2.35 (1.85–2.98) 1.78 (1.34–2.36) NA
Harrell’s C (95% CI) 0.70 (0.67–0.73) 0.79 (0.76–0.81) 0.81 (0.78–0.83) 0.80 (0.78–0.82)
Grønnesby and Borgan test 0.04 0.99 0.40 0.18
IDI % (P value) NA 0.009 (P = 0.005) 0.002 (P = 0.16) NA
Model 1, crude, only MR-proADM; model 2, as in model 1 and also adjusted for age and sex; model 3, as in model 2 and also adjusted for BMI,
smoking, systolic blood pressure, cholesterol-to-HDL ratio, duration of diabetes, HbA1c, history of CVD, use of ACEi/ARB, log SCr, and log ACR; model
4, as in model 3 but without MR-proADM.
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test; a nonsignificant result means an
acceptable calibration (30). Statistical
analyses were performed using SPSS
version 20.0 for Windows (IBM SPSS
Statistics for Windows; IBM Corp.,
Armonk, NY) and STATA version 11
(StataCorp LP, College Station, TX).
Results were expressed as mean6 SD or
median (interquartile range [IQR]) for
normally distributed and nonnormally
distributed data, respectively. A two-
sidedP,0.05was considered significant.
RESULTS
From 1,243 patients with baseline
measurements of MR-proADM, 1,194
(96%) had complete data on all
confounders. Two outliers were
excluded, one patient with a MR-
proADM value of 5.5 nmol/L and one
patient with an undetectable level.
Ultimately, 1,192 patients were
included in the multivariate analyses.
Baseline characteristics are presented
in Table 1. Variables that were
relevantly different between tertiles of
MR-proADM concentrations were age,
history of CVD, systolic blood pressure,
ACR, and use of ACEi/ARB (see Table 1).
The median MR-proADM
concentration was 0.49 nmol/L (IQR
0.39–0.63). Besides a higher SCr among
patients without MR-proADM
measurements (98.06 20.9 vs. 95.06
21.0 mmol/L, P = 0.02), there were no
other significant differences between
baseline characteristics of patients
with and without MR-proADM
measurements or from patients with




The median follow-up period was 5.6
years (IQR 3.1–10.1), 9.7 years for the
patients entering the study in 1998, and
3.1 years for those included in 2001. Of
the 1,243 included patients, 388 (31%)
Figure 1—Kaplan-Meier survival curves (CV mortality) for tertiles of MR-proADM.
Figure 2—Kaplan-Meier survival curves (all-cause mortality) for tertiles of MR-proADM.
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had died, with 168 (12%) deaths
attributable to CV causes. The median
baseline MR-proADM concentration of
0.45 nmol/L in survivors was
significantly lower than the median MR-
proADM level of 0.59 nmol/L in
nonsurvivors (P, 0.001). From the 681
patients with normoalbuminuria at
baseline, 182 (26.7%) developed
albuminuria.
In the Cox regression analyses, log2 MR-
proADM was significantly associated
with new-onset albuminuria, CV
mortality, and all-cause mortality,
except for new-onset albuminuria in
model 3 (see Table 2 and Figs. 1 and 2). If
model 3 is compared with model 4
(without MR-proADM), the model fit
was not significantly better for new-
onset albuminuria (P = 0.089), whereas
for CV mortality and all-cause mortality,
including MR-proADM in the fully
adjusted model improved the model fit
significantly (P = 0.002 and P , 0.001,
respectively). Harrell’s C valueswere not
different for new-onset albuminuria and
only marginally higher for CV mortality
and all-causemortality (see Figs. 3 and 4).
In addition, the IDI values were,1% for
all models. The IDI values for model 2
Figure 3—Receiver operating characteristic curves at the end of the follow-up period for CV mortality.
Figure 4—Receiver operating characteristic curves at the end of the follow-up period for all-cause mortality.
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predicting CV and all-cause mortality
were significant, indicating that MR-
proADM had additional value on top of
age and sex. In the fully adjustedmodels,
the IDI values were not significant. The
Grønessby and Borgan P values in Table
2 indicate that since predicted
probabilities correspond well with
observed risks (except for the crude
model and model 3 predicting CV
mortality), all models were well
calibrated.
Adding estimated glomerular filtration
rate to models 3 and 4 instead of SCr
produced similar results. The
Schoenfeld residuals showed no
substantial deviations, supporting the
assumption of proportional hazards.
The association between the presence
or absence of a MR-proADM
measurement and new-onset
albuminuria and CV and all-cause
mortality in the combined cohort of
1,689 patients was also tested in a
multivariable Cox regression analysis;
no significant associations with the
presence or absence of a MR-proADM
measurement were present.
CONCLUSIONS
Increased plasma MR-proADM levels
were associated with CV and all-cause
mortality in patients with type 2
diabetes after long-term follow-up. No
independent associations were found
between MR-proADM and new-
onset albuminuria. This is the first study
evaluating the relationship between
MR-proADM and mortality in patients
with type 2 diabetes and the first to
evaluate the relationship with new-
onset albuminuria (13,16,19,20,24–26,31).
The age- and sex-adjusted MR-proADM
levels were associated with new-
onset albuminuria, although there was
no significant relationship after
adjusting for multiple risk factors. MR-
proADM levels were also associated
with several baseline risk factors (i.e.,
BMI, systolic blood pressure, and SCr).
Although there was no independent
relationship, the development of new-
onset albuminuria was related to the
same risk factors, e.g., blood pressure,
factors that also increase MR-proADM
levels. Thus, MR-proADM could possibly
act as a unified marker for several
known risk factors.
Previous observations showed that
increased levels of MR-proADM were
associated with endothelial dysfunction
(6); through this mechanism, the
association with CV and all-cause
mortality could also be explained.
Despite mutual correlations between
MR-proADM and baseline risk factors,
MR-proADM, corrected for an extensive
set of risk factors, was independently
associated with CV and all-cause
mortality. Adding an extensive set of risk
factors to the age- and sex-corrected
MR-proADM levels increased the
Harrell’s C from 0.78 to 0.82, indicating
that the age- and sex-corrected serum
levels of MR-proADM were able to
predict CV mortality to some degree.
The improvement in risk prediction by
adding MR-proADM to a fully adjusted
model was significant, as measured by
the improvement in model fit. Despite
the fact that the model fit significantly
improved, the relevancy of this small
effect on risk prediction, expressed by
the change in Harrell’s C, is not clear.
This small improvement in risk
prediction seems to be in line with
results fromprevious biomarker studies,
in which addition of biomarkers to a
comprehensivemodel, with overlapping
risk factors, has only a little beneficial
effect. Important risk factors, even lipid
abnormalities, show only small or no
improvements in Harrell’s C when
added to a combination of other known
risk factors (32).
MR-proADM levels were measured in
serum plasma, and from these data, it
remains unclear whether on a cellular
level ADM, expressed by the serum level
of MR-proADM, acts in a paracrine
fashion or plays a relevant role in plasma
through endocrine effects (5).
The strengths of this study were a
relative long-term follow-up and the
number and completeness of
confounders used in the multivariate
model. This study also has several
limitations. First, selection bias may
have occurred, because patients whose
MR-proADM had not been measured
were excluded from statistical analysis.
However, no relevant differences were
found in Cox regression analysis
between groups in which MR-proADM
had or had not been measured. Second,
MR-proADM was measured only once,
without correction for potential
variability in concentrations.
Fortunately, the intra-assay and
interassay variability are known to be
low and values are stable (17). Third,
unlike the statistically significant
increase in fit of the fully adjusted
models for CV and all-cause mortality,
Harrell’s C values did not change much
and the value of the IDI was not
significant when MR-proADM was
added to the fully adjusted model. Also,
the results of the IDI values need to be
interpreted with caution, ranges of
meaningful improvements are not
established, values are strongly
dependent on the number of events, the
IDI was not yet developed in the context
of censored data, and the value of the
IDI can, by accident or deliberately, be
inflated (29). Fourth, the relatively small
sample size in the analysis of the
relationship between MR-proADM
levels and new-onset albuminuria does
not fully exclude the presence of an
independent relationship.
In conclusion, ADM is increasingly being
studied for its prognostic properties in a
variety of disease states. This is the first
report showing an independent
association between increased plasma
MR-proADM levels and CV and all-cause
mortality after years of follow-up in
patients with type 2 diabetes who were
treated in primary care. In this study, an
extensive set of known risk factors
predicted mortality to a high degree.
When combining MR-proADM with
these risk factors, there was little added
benefit of using MR-proADM in risk
prediction. Future studies are needed to
clarify the role of increased plasma MR-
proADM levels on a cellular level and to
establish whether MR-proADM could
have a role in predicting adverse
outcomes, including mortality, in
individual patients with type 2 diabetes.
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